Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neha Panjwani

MYSTERIOUS: Regeneron pharmaceuticals quarterly earnings preview what you need to know - You Need To See This

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $81.6 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. The biotechnology company is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Friday, Jan. 30. 

Ahead of the event, analysts expect REGN to report a profit of $8.06 per share on a diluted basis, down 18.6% from $9.90 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.